Alzheimer's Drugs Show 'Trivial' Benefits, Review Finds
The Spin
Narrative A
Anti-amyloid Alzheimer's drugs don't deliver the breakthrough patients deserve — their effects on cognitive decline are trivial, and functional improvements are small at best. Lumping failed drugs with newer ones skews the picture, but even lecanemab and donanemab only slow decline by months. That's not a game-changer — that's a consolation prize dressed up as a cure.
Narrative B
Dismissing all anti-amyloid drugs as trivial is junk science — the Cochrane review mixed mostly failed, discontinued drugs with the two actually approved treatments, producing a conclusion that tells us nothing useful. Leqembi and Kisunla earned FDA approval by demonstrably slowing cognitive decline, and lumping them with drugs that never made it to market is like grading a restaurant on food it never served.